Almirall S.A. Stock
Price
Target price
€9.11
€9.11
1.340%
0.12
1.340%
-
19.07.24 / Tradegate
WKN: A0MU8Y / Symbol: LBTSF / Name: Almirall / Stock / Pharmaceuticals / Mid Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Almirall S.A. Stock
There is an upward development for Almirall S.A. compared to yesterday, with an increase of €0.12 (1.340%).
Pros and Cons of Almirall S.A. in the next few years
Pros
?
W********* I********* f** t** n*** y****
?
S********** s********
?
G***** c******* t* c**********
Cons
?
B****
?
C******** o* t** e**********
?
M***** P*******
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Almirall S.A. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Almirall S.A. | 1.340% | -2.410% | -5.498% | 7.303% | 7.556% | -39.788% | - |
| Sihuan Pharmaceutical Holdings Group Ltd. | -1.630% | -0.820% | -1.626% | -24.375% | -11.679% | -80.732% | -67.560% |
| Orion Corp. B | -1.180% | -3.569% | 3.003% | 12.457% | 0.152% | 12.297% | 20.274% |
| Recordati SpA | -0.780% | 0.098% | 3.616% | 12.508% | 4.209% | 0.552% | - |
News
NICE Recommends Ebglyss (lebrikizumab) for Use in Moderate to Severe Atopic Dermatitis in the NHS England in Eligible Adolescents and Adults
Almirall S.A. (BME: ALM), a global biopharmaceutical company dedicated to medical dermatology, announced today that the National Institute for Health and Care Excellence (NICE) has recommended
Almirall Launches Act4Impact – its Updated Sustainability Strategy Setting Ambitious Targets for 2030
Almirall S.A. (BME: ALM), a global pharmaceutical company dedicated to medical dermatology, launched its new sustainability strategy Act4Impact 2030 today. The updated strategy aims at transforming
Almirall’s Ilumetri® (tildrakizumab) Restores and Maintains Wellbeing of Patients With Moderate-to-severe Plaque Psoriasis to the Levels of the General Population for up to 1 Year1
Almirall, a global pharmaceutical company dedicated to medical dermatology, announced today new data from the real-world evidence clinical study called “POSITIVE” demonstrating that Ilumetri®